Invests in synthetic biology, reproductive health, skin microbiome and nutrition startups
“Illumina Accelerator is pleased to have such a promising group of startups join our growing genomics community,” said
The selected startups for the third funding cycle are:
MetaMixis, Inc., a synthetic biology company spun out of The University of British Columbia, is specializing in the rapid discovery of enzymes and pathways to produce bio-based materials and chemicals. NextGen Jane, Inc., a novel med-tech company based on technology developed at Harvard University, is offering women insights into their reproductive health through a genomics-driven approach to tracking biological changes predictive of disease. Skinomics, Inc., a skin microbiome company formed by faculty members from the University of California, Los Angeles, is harnessing genomics information from the cutaneous microbiome to create advances in skin care, with a current focus on acne. Vitagene, Inc., a health technology company, is leveraging genomic science to offer physicians a platform for data-driven care and delivers highly customized products and services for optimal health.
During the six-month Accelerator funding cycle, each startup will gain access to business guidance and fully operational lab space in the
“Illumina Accelerator continues to propel talented entrepreneurs by providing unparalleled resources to help advance their genomics startups,” said Amanda Cashin, Ph.D., co-founder and Head of
Applications for the Illumina Accelerator Spring 2016 funding cycle are due by March 1, 2016. To apply, visit www.illumina.com/accelerator.
About Illumina Accelerator
Illumina Accelerator is the world’s first business accelerator focused solely on creating an innovation ecosystem for the genomics industry. It provides select startups with seed investment, business guidance, access to Illumina’s sequencing systems and reagents, and fully operational lab space in the
About Illumina, Inc.
This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.